Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 1153-1160

  Anforth, R M ^a,b   Blumetti, T C M P ^a   Kefford, R F ^b,c,d   Sharma, R ^a,c,e   Scolyer, R A ^b,d,f   Kossard, S ^g   Long, G V ^b,c,d   Fernandez Penas P ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g SKIN AND CANCER FOUNDATION AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; MUTANT PROTEIN; PROTEIN P16;

ACNE; CANCER PATIENT; CELL PROLIFERATION; CLINICAL FEATURE; DRUG SELECTIVITY; EPIDERMOID CYST; HAIR LOSS; HUMAN; HYPERKERATOTIC ACTINIC KERATOSIS; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; KERATOACANTHOMA; METASTATIC MELANOMA; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLANTAR HYPERKERATOSIS; PRIORITY JOURNAL; REVIEW; SEBORRHEIC KERATOSIS; SKIN BIOPSY; SKIN CARCINOMA; SKIN MANIFESTATION; SUN EXPOSURE; SYSTEMATIC REVIEW; TRANSIENT ACANTHOLYTIC DERMATOSIS; VERRUCA VULGARIS; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; FEMALE; HUMANS; IMIDAZOLES; KERATINOCYTES; MALE; MELANOMA; MIDDLE AGED; MUTATION; OXIMES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN DISEASES; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84868193136     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11155.x     Document Type: Review

References (31)

1. Thompson JF, Scolyer RA, Kefford RF,. Cutaneous melanoma in the era of molecular profiling. Lancet 2009; 374: 362-5.
2. Lee CC, Faries MB, Wanek LA, et al. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009; 27: 3489-95.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
4. Atkins MB, Long GV, Warneke CL, et al. Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): preliminary report of the PHAMOUS study. J Clin Oncol 2010; 28 (Suppl.): Abstract 8516.
5. Dhomen N, Marais R,. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009; 23: 529-45, ix.
6. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-46.
7. U.S. National Institutes of Health. NCT01227889. A study comparing GSK2118436 to dacarbazine (DTIC) in previously untreated subjects with BRAF mutation positive advanced (stage III) or metastatic (stage IV) melanoma. Available at: ClinicalTrials.gov (last accessed 22 July 2012).
8. Chapman PB, Hauschild A, Robert C, et al. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. J Clin Oncol 2011; 29: LBA4 (Abstract).
9. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
10. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
11. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28 (Suppl.): Abstract 8503.
12. Kefford RF, Arkenau H-T, Brown MP, et al. Selective inhibition of oncogenic BRAF V600E/K/D by GSK2118436: evidence of clinical activity in subjects with metastatic melanoma. Pigment Cell Melanoma Res 2010; 23: 912 (Abstract).
13. Long GV, Kefford RF, Carr PJA, et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets). Ann Oncol 2010; 21: viii12 (LBA27) (Abstract).
14. Falchook GS, Long GV, Kurzrock R, et al. RAF inhibitor GSK2118436 is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers. Lancet 2012; 379: 1893-901.
15. Robert C, Arnault JP, Mateus C,. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011; 23: 177-82.
16. Youl PH, Janda M, Aitken JF, et al. Body-site distribution of skin cancer, pre-malignant and common benign pigmented lesions excised in general practice. Br J Dermatol 2011; 165: 35-43.
17. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011; 29 (Suppl.): Abstract 8509.
18. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158: 592-6.
19. Lacouture ME, Reilly LM, Gerami P, et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19: 1955-61.
20. Zimmer L, Livingstone E, Hillen U, et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148: 357-61.
21. Siegel DH, McKenzie J, Frieden IJ, et al. Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome. Br J Dermatol 2011; 164: 521-9.
22. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
23. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
24. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-30.
25. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
26. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.
27. Lacouture ME, Chapman PB, Ribas A, et al. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. J Clin Oncol 2011; 29 (Suppl.): Abstract 8520.
28. Conscience I, Jovenin N, Coissard C, et al. P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas. Eur J Dermatol 2006; 16: 518-22.
29. Hodges A, Smoller BR,. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin. Mod Pathol 2002; 15: 1121-5.
30. Mulvany NJ, Allen DG, Wilson SM,. Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology 2008; 40: 335-44.
31. Chang TG, Wang J, Chen LW, et al. Loss of expression of the p16 gene is frequent in malignant skin tumors. Biochem Biophys Res Commun 1997; 230: 85-8.